When you absolutely have to recruit patients on time.
Home Company News A clinical study of safety and immunogenicity of a vaccine against Hepatitis B in adult healthy subjects is starting at Accell
A clinical study of safety and immunogenicity of a vaccine against Hepatitis B in adult healthy subjects is starting at Accell
immunogenicity of a recombinant vaccine against Hepatitis B in adult healthy subjects. Accell will be responsible for regulatory, clinical, data management, statistics and medical writing and will randomize 100 subjects at Russian sites.
Company News
our SERVICES MENU
From clinical research associates to hands-on founders, we fiercely pursue our strategic goal: deliver on schedule. We think of ourselves as your development partner, not a vendor.
